Max Adler, MD
Dermatology · Dallas, TXNPI 1801835434
Payments from drug & device makers
Across 500 payments — averaging $52.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Galderma Laboratories, L.p.$839
- E.r. Squibb & Sons, L.L.C.$793
- Sun Pharmaceutical Industries Inc.$682
- Dermavant Sciences, Inc.$669
- Amgen$668
- plus $5K from 30 others
What the payments were for
- Food & beverage$12,73949%
- Education$1080%
- Gifts$13,23551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 195 | $17,512 |
| Galderma Laboratories, L.p. | 32 | $839 |
| E.r. Squibb & Sons, L.L.C. | 26 | $793 |
| Sun Pharmaceutical Industries Inc. | 20 | $682 |
| Dermavant Sciences, Inc. | 30 | $669 |
| Amgen | 19 | $668 |
| Pfizer | 23 | $624 |
| Arcutis Biotherapeutics, Inc. | 14 | $538 |
| LEO Pharma Inc. | 23 | $531 |
| Regeneron Healthcare Solutions, Inc. | 16 | $515 |
| Johnson & Johnson | 15 | $497 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $320 |
| UCB, Inc. | 7 | $244 |
| Incyte Corporation | 10 | $193 |
| Lilly USA, LLC | 4 | $175 |
| Mayne Pharma Commercial LLC | 19 | $155 |
| Novartis | 5 | $141 |
| Sensus Healthcare, Inc. | 2 | $123 |
| Sanofi | 5 | $121 |
| Bristol Myers Squibb | 1 | $112 |
| Merz North America, Inc. | 2 | $109 |
| Almirall LLC | 6 | $106 |
| VYNE Pharmaceuticals Inc. | 1 | $87 |
| LNHC, Inc | 3 | $46 |
| Verrica Pharmaceuticals Inc. | 2 | $35 |
| Organon | 2 | $33 |
| Cipher Pharmaceuticals US LLC | 1 | $28 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $25 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $25 |
| Journey Medical Corporation | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Revance Therapeutics, Inc. | 1 | $20 |
| Dermira, Inc. | 1 | $17 |
| Aclaris Therapeutics, Inc. | 1 | $15 |
| Medline Industries LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,082 in reported general payments places this provider in the 85th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 47 | $1,030 |
| Clobetasol Propionate | 29 | $878 |
| Mometasone Furoate | 16 | $318 |
| Cephalexin | 12 | $168 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Dallas
- Jennifer CatherDallas$4.9M
- Martin MenterDallas$3.7M
- So Yeon PaekDallas$3.5M
- Ross RaduskyDallas$3.3M
- Joseph MerolaDallas$2.1M
- William AbramovitsDallas$1.8M
- Donald GlassDallas$847K
- Kristel PolderDallas$761K
- Mary HornerDallas$457K
- Gregory PetersonDallas$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.